Review

MicroRNAs and Cardiac Regeneration

Conrad P. Hodgkinson, Martin H. Kang,* Sophie Dal-Pra,* Maria Mirotsou, Victor J. Dzau

Abstract: The human heart has a limited capacity to regenerate lost or damaged cardiomyocytes after cardiac insult. Instead, myocardial injury is characterized by extensive cardiac remodeling by fibroblasts, resulting in the eventual deterioration of cardiac structure and function. Cardiac function would be improved if these fibroblasts could be converted into cardiomyocytes. MicroRNAs (miRNAs), small noncoding RNAs that promote mRNA degradation and inhibit mRNA translation, have been shown to be important in cardiac development. Using this information, various researchers have used miRNAs to promote the formation of cardiomyocytes through several approaches. Several miRNAs acting in combination promote the direct conversion of cardiac fibroblasts into cardiomyocytes. Moreover, several miRNAs have been identified that aid the formation of inducible pluripotent stem cells and miRNAs also induce these cells to adopt a cardiac fate. MiRNAs have also been implicated in resident cardiac progenitor cell differentiation. In this review, we discuss the current literature as it pertains to these processes, as well as discussing the therapeutic implications of these findings. (*Circ Res*. 2015;116:1700-1711. DOI: 10.1161/CIRCRESAHA.116.304377.)

Key Words: cardiac myocyte ∎ microRNA ∎ regeneration ∎ stem cell ∎ transdifferentiation

Myocardial infarction (MI) leads to significant cardiomyocyte cell death. These specialized cells are not replaced in substantial numbers after injury, leading to disproportionate thinning of the heart wall and severely impaired cardiac function. Moreover, cardiac fibroblasts, which form a significant proportion of the heart, are expanded further, leading to excessive fibrosis and scar formation. Fibrotic remodeling of the injured myocardium negatively impacts contractility and electric conduction, which over time causes a further deterioration in cardiac function.[1]

Several strategies are being actively pursued in cardiac regenerative medicine. Replacing lost cardiomyocytes by injecting cardiac progenitors, cardiospheres, or cardiac myocytes derived from inducible pluripotent stem cells or embryonic stem cells (iPS/ESCs) has been researched intensively. Others have focused instead on the cardiomyocytes by enabling them to enter cell cycle to replicate and proliferate as a means to generate new muscle cells. However, these approaches, although encouraging, face significant challenges. Recently, much excitement has been turned to the cardiac fibroblast

Nonstandard Abbreviations and Acronyms	
dKO	double knockout
ESC	embryonic stem cell
GMT	Gata4, Mef2C, and Tbx5
Hand	Heart– and neural crest derivatives–expressed protein
iPS	inducible pluripotent stem cell
MEF	murine embryonic fibroblasts
MHC	myosin heavy chain
MI	myocardial infarction
miRNA(s)/miR(s)	microRNA(s)
OKSM	Oct4, Klf4, Sox2, and cMyc
tdTomato	tandem dimer Tomato (fluorescent protein)
TGF-β	transforming growth factor-β

population in the scar tissue with a view to turning these cells into cardiomyocytes.[2] Taking cues from heart developmental programs,[3–5] direct reprogramming of fibroblasts to cardiomyocytes has been achieved recently by specific combinations of transcription factors[6–8] and microRNAs (miRNAs).[2,9–11]

In this review, we discuss the role of miRNAs in cardiac development, as well as in indirect and direct cardiac reprogramming. Based on this scientific knowledge, we discuss the strategy of targeting miRNAs for cardiac regeneration therapy.

MiRNA Biology

MiRNAs are small noncoding RNAs belonging to a class of small silencing RNAs that are critically important in the post-transcriptional regulation of genes.[12,13] Indeed, most mammalian mRNAs are targets of miRNAs.[14–16] MiRNAs have been demonstrated to play an important role in the differentiation and development of many cells and tissues, including the heart.[17–27] Moreover miRNAs are important for stem cell differentiation, as well as indirect and direct reprogramming to multiple lineages.[9,28–30]

The RNA polymerase II enzyme transcribes MiRNAs and the resulting transcript is known as a primary-miRNA. The primary-miRNA is ≈1000 nucleotides in length, possesses a 5′ cap, a middle stem loop structure, and a 3′ polyadenylated tail.[31] Primary-miRNAs are processed further into pre-miRNAs by the Microprocessor complex.[32] Drosha, a component of the Microprocessor complex, cleaves the 5′ cap and 3′ poly (A) tail leaving an ≈65 bp stem loop structure containing the mature miRNA.[16] After cleavage by Drosha, the pre-miRNA is transported from the nucleus into the cytoplasm. Once in the cytoplasm, the pre-miRNA is cleaved further by the RNase III-type endonuclease Dicer (double-stranded RNA-specific endoribonuclease) into a smaller fragment containing the mature miRNA.[33] In humans, the Dicer-generated small dsRNA fragment containing the mature miRNA is loaded onto one of 4 Argonaute (Ago) proteins, Ago 1–4,[34] an action facilitated a heat shock cognate—heat shock protein 90 complex.[35] Within this complex, which is named the pre-RNA-induced silencing complex, processing occurs to generate the final single-stranded mature miRNA.[36] The single-stranded miRNA, associated with Ago 1–4, constitutes the mature RNA-induced silencing complex complex. This

is the final functional unit that mediates post-transcriptional repression of a target.

MiRNAs in Cardiac Development and Function

Cardiac-specific deletions of Dicer gave the first evidence of a role of miRNAs in cardiac development.[37–40] Deletion of Dicer in Nkx2-5 (homeobox protein Nkx2-5) cardiac progenitor cells induced development defects in the heart, such as cardiac edema and poorly developed ventricular myocardium, leading to embryonic lethality at E12.5 because of cardiac failure.[40] The use of an alternative allele for the Nkx2.5-Cre transgene, which allowed mutant mice to survive beyond E13.5, highlighted additional role for Dicer in cardiac outflow tract alignment and chamber septation.[39] Using an α-myosin heavy chain (αMHC) promoter to delete Dicer expression at a later stage of cardiac development caused impairment of cardiac function through dysregulated cardiac contractile protein expression, disrupted sarcomeric structure, and disarray of myofibers. Mice quickly developed dilated cardiomyopathy and heart failure with lethality observed within 4 days of birth.[37] Similarly, using a tamoxifen-inducible α-MHC-Cre, another group depleted Dicer in the postnatal heart. Loss of Dicer in juveniles resulted in mild cardiac remodeling and premature death within 1 week, whereas deletion in adults led to severe hypertrophy, myofiber disarray, ventricular fibrosis, and reactivation of a fetal gene transcription program.[38]

The study of individual mature miRNAs has demonstrated their importance in cardiac development.

MiRNA-1 is produced from 2 loci. The 2 mature miRNAs are called miRNA-1-1 and miRNA-1-2 to distinguish them from each other. MiRNA-1-1 and miRNA-1-2, cotranscribed with miRNA-133-a2 and miRNA-133-a1, respectively, are expressed specifically in cardiac and skeletal muscle with expression increasing substantially from E8.5 to adulthood.[28,41,42] Transcription of miRNA-1/miRNA-133 in heart and skeletal muscle is regulated by serum response factor, myocardin, myogenic differentiation 1, and myocyte enhancer factor (Mef2) transcription factors.[41,43] Expression of serum response factor is repressed by miRNA-133 in myoblasts, suggesting a negative regulatory loop.[42]

Overexpression of miRNA-1 in the developing mouse heart inhibits proliferation of ventricular cardiomyocytes. Developmental arrest occurs at E13.5 secondary to thinning of ventricle walls and heart failure. Heart- and neural crest derivative–expressed (Hand)-2, a direct target of miRNA-1, may mediate these effects.[41] Similar findings have been observed in Xenopus,[42] suggesting miRNA-1 is important for the development of the vertebrate heart.

MiRNA-1-2 deletion in mice induces a range of phenotypes.[40] Approximately half of the miRNA-1-2 null mice died between E15.5 and birth from severe ventricular septation defects. The surviving miRNA-1-2 null mice possessed thickened cardiac walls arising from increased cardiomyocyte proliferation.[40] Moreover, conduction defects were observed because of de-repression of Irx5, and several null mice died within 2 to 3 months from dilatation of the heart and ventricular dysfunction.[40] MiRNA-1-1 null mice are similar, with partial lethality, mild ventricular dilation, and conduction defects all being observed.[44]

Partially penetrant lethality in single miRNA-1-1 or miRNA-1-2 null mice may reflect compensation by the remaining miRNA-1. To elucidate the role of miRNA-1, double mutant mice for miRNA-1-1 and miRNA-1-2 (miRNA-1 double knockout [dKO]) were recently engineered by 2 groups.[44,45] Heidersbach et al[44] found that miRNA-1 dKO mice died uniformly before P10 because of severe cardiac dysfunction, including ventricular septal defects, heart chamber dilatation, abnormal conduction, and sarcomere disruption. In the miRNA-1 dKO mice, Telokin, the smooth muscle–restricted inhibitor of myosin light chain-2 phosphorylation, was ectopically expressed in the myocardium. Telokin was found to be a direct target of miRNA-1, suggesting that miRNA-1 promotes cardiac development and sarcomeric organization by repressing the smooth muscle gene program.[44] Similarly miRNA-1 dKO mice generated by Wei et al[45] died by P17 from heart dilatation, an increase in cardiac mass arising from elevated cardiomyocyte proliferation, and sarcomeric defects. However, ventricular septal defects were not observed. In the miRNA-1 dKO mice, increased expression of the nuclear receptor estrogen-related receptor 2β, a direct miRNA-1 target, activated a fetal gene program, which included the expression of fetal sarcomere-associated genes. Expressing estrogen-related receptor 2β in heart tissue mimicked the miRNA-1 dKO phenotype, further validating the model.[45]

The differences between these 2 studies may reflect that miRNA-1 controls heart development through multiple pathways, the methods used to generate the null mice, or genetic background.

MiRNA-133 is cotranscribed with miRNA-1 and shares a commonality of function during heart development. Overexpression of miRNA-133 in Xenopus induces defects in cardiac looping and chamber formation.[42] Zebrafish regenerate their hearts after severe injury by increasing cardiomyocyte proliferation. Interestingly, transgenic expression of miRNA-133 inhibited this process in part by targeting the cell junction protein connexin-43 and the cell cycle regulator monopolar spindle 1.[46] To gain further insights into the role of miRNA-133 in the development of the mammalian heart, both miRNA-133a1 and miRNA-133a2 were ablated in mice[47] (miRNA-133 dKO). The phenotype of the miRNA-133 dKO mice was found to be somewhat similar to that of the miRNA-1 dKO. Approximately half of miRNA-133 dKO mice died postnatally because of ventricular septal defects, increased cardiomyocyte proliferation, and aberrant expression of smooth muscle genes.[47] Surviving mutants displayed severe cardiac dysfunction with death from heart failure within 6 months. The miRNA-133 dKO phenotype was attributed in part to the increased expression of cyclinD2, a negative regulator of cell cycle, and serum response factor, a coactivator of smooth muscle genes.[47] The high level of miRNA-133 expression in the adult heart may also be important for homeostasis of the organ because knockdown of miRNA-133 promoted hypertrophy in one report[48] and overexpression of miRNA-133 inhibits hypertrophic stimuli.[48,49] Calcineurin levels increase during cardiac hypertrophy, and this protein may act in a reciprocal fashion with miRNA-133. Overexpression of miRNA-133 inhibited calcineurin expression, and inhibition of calcineurin by cyclosporin-A prevented miRNA-133 downregulation in a hypertrophic model.[50]

Mice with a combined deletion of the 2 miRNA-1/miRNA-133a clusters (miRNA-1/133 dKO) have also been generated.[51] Genetic ablation of either cluster was not detrimental to mice development and survival. However, deletion of both miRNA-1/133a clusters was embryonically lethal. MiRNA-1/133 dKO mice displayed severe cardiac defects with thinning of ventricular walls and decreased cardiomyocyte proliferation. These effects were associated with increased smooth muscle gene expression, notably that of the smooth muscle regulator myocardin. Overexpression of myocardin recapitulated many aspects of the miRNA-1/133 dKO phenotype, arresting the developing cardiomyocytes in an immature state. Interestingly, myocardin activated the transcription of both miRNA-1/133a clusters, suggesting that a negative feedback loop exists to restrict smooth muscle gene expression and to promote cardiomyocyte maturation.[51]

In mammals, cardiomyocyte contraction depends on 2 MHC proteins. The faster contracting isoform αMHC is expressed predominantly in adult mouse heart, whereas the embryonic heart expresses the slower contracting isoform βMHC.[52] In humans, βMHC expression continues into adulthood; however, hypertrophy induces the β form in humans and rodents alike.[53] Expression of α- and β-MHC isoforms is controlled by miRNA-208a, miRNA-208b, and miRNA-499[54–56]. MiRNA-208a and miRNA-208b are encoded in an intron of the αMHC and βMHC gene, respectively. Mice null for miRNA-208a are viable and show no changes in heart structure ≤20 weeks. However, a progressive decrease in heart contractility was observed from 2 months postbirth, and this was concomitant with aberrant expression of fast skeletal muscle contractile proteins.[54] Despite the lack of gross structural changes in heart structure in miRNA-208a null mice, there are significant electric conduction defects, with a lack of P waves (atrial depolarization) preceding QRS complexes (right and left ventricle depolarization) and significantly prolonged PR intervals (the interval from where the P wave begins until the beginning of the QRS complex).[55] Further underlying a role in the heart's electric conduction system, overexpression of miRNA-208a induced arrhythmia.[55] MiRNA-208a null mice fail to show a hypertrophic response after such stimuli as transverse aortic banding and calcineurin.[54,55] Moreover, there was no increase in βMHC expression,[54,55] indicating that miRNA-208a controls expression of this MHC isoform. Thyroid signaling is important in the switch of MHC expression after birth, activating expression of αMHC, whereas inhibiting the expression of βMHC.[57] MiRNA-208a was found to be important in this process by directly targeting thyroid hormone receptor–associated protein 1.[54]

MiRNA-208a not only controls the expression of βMHC, but also that of the closely related βMHC isoform Myh7b.[56] Both βMHC and Myh7b are slow myosins; the genes for these proteins contain intronic miRNAs, miRNA-208b, and miRNA-499, respectively. These miRNAs are important in the specification of the identity of muscle fibers by stimulating slow myofiber gene programs at the expense of those that control fast myofiber gene expression.[56] Mice lacking the miRNA-499 gene have no obvious developmental defects.[56] However, overexpression of miRNA-499 promotes hypertrophy.[58,59]

The mammalian heart increases in size dramatically during embryonic development predominantly via an increase in cardiomyocyte numbers. After birth, mammalian cardiomyocytes exit the cell cycle, and this has a negative impact on cardiac regeneration after injury.[60–62] In contrast to mammals, lower vertebrates, such as zebrafish, retain the ability to regenerate their hearts throughout life. In the case of the zebrafish, this natural ability is particularly robust because complete cardiac regeneration has been observed even when ~20% of the ventricular myocardium was removed.[63] Cardiomyocyte dedifferentiation followed by re-entry into the cell cycle underlies this process.[64] MiRNAs are critically important for cardiomyocyteproliferation. In a recent study, cardiac regeneration in the zebrafish was found to be dependent on a decrease in the levels of miRNA-99/100 and Let-7a/c[65]. Interestingly, this did not occur in the murine heart after injury. When the authors forcibly reduced miRNA-99/100 and Let-7a/c expression after MI in the mouse recovery was observed, indicating a species conserved miRNA program for cardiac regeneration.[62,65] The miRNA-17-92 cluster has also been shown to be important for cardiomyocyte proliferation. Overexpression of this miRNA cluster induced cardiomyocyte proliferation in neonatal and adult hearts. Interestingly, transgenic overexpression of miRNA-17-92 in adult cardiomyocytes protected the heart from MI-associated injury. The miRNA-17-92 cluster was found to reduce the expression of phosphatase and tensin homolog, a proliferation repressor.[66] Studies have demonstrated that withdrawal of cardiomyocytes from the cell cycle is dependent on specific miRNAs. A microarray analysis for miRNAs, differentially regulated between P1 and P10, the point at which mouse cardiomyocytes exit the cell cycle, identified miRNA-195 as the most highly upregulated miRNA. Overexpression of this miRNA in the embryonic heart caused premature cell cycle exit, ventricular hypoplasia, and ventricular septal defects. Checkpoint kinase 1 was identified as the miRNA-195 target. Knockdown of the miRNA-15 family, to which miRNA-195 belongs, was associated with increased cardiomyocyte proliferation[67] and cardiac regeneration.[68,69] MiRNA-29a also induces cell cycle arrest in cultured cardiomyocytes by targeting cyclin-D1.[70] MiRNAs are also important for promoting cardiomyocyte proliferation. Using a high-throughput functional screening method to identify miRNAs that could promote neonatal cardiomyocyte proliferation, Eulalio et al identified several candidates. Two of these candidates, hsa-miRNA-590 and hsa-miRNA-199a, induced ex vivo cultured adult cardiomyocytes to re-enter the cell-cycle. Moreover, these cells also showed signs of cytokinesis. Indeed, in vivo administration of these miRNAs markedly stimulated cardiac regeneration post-MI.[71] Taken together, the results of the above studies demonstrate the potential of activating or antagonizing specific miRNAs to induce cardiomyocyte proliferation for cardiac regenerative therapy.

MiRNAs and the Formation of iPS Cells

iPS are an important source of cells for cardiac regeneration because they can form all of the cardiovascular cell types on differentiation.[72,73] Indeed, intramyocardial delivery of iPS after MI has been shown to restore contractile performance, cardiac tissue, and ventricular wall thickness.[74–76]

The first iPS cells were generated when Takahashi and Yamanaka overexpressed Oct4, Sox2, Klf4, and cMyc (OKSM) in fibroblasts.[77] The formation of iPS cells occurs via the dedifferentiation of somatic cells, and this requires shifts in the patterns of expression of thousands of genes.[78,79] A single miRNA can influence many hundreds of genes, and as such, there has been much interest in their possible role in forming iPS cells. Indeed several reports have shown that miRNAs can promote the formation of iPS cells either alone[80,81] or in combination with the OKSM factors.[82]

During the process of converting to iPS cells, somatic cells adopt a pluripotent cell cycle phenotype that is characterized by rapid proliferation, a shortened S-phase, and low expression of cell cycle inhibitors, such as p21 and p53[83,84]. Moreover, activation of the p53-p21 pathway suppresses iPS formation.[85] Several miRNAs are involved in ESC proliferation,[86] and they have been exploited to generate iPS cells. MiRNA-302d, miRNA-291, miRNA-294, and miRNA-295 promote proliferation in ESCs. For example, when ectopically expressed in ESCs lacking the miRNA microprocessor subunit Dgcr8 (DiGeorge Syndrome Critical Region 8), which lack canonical miRNAs and proliferate slowly, miRNA-302d, miRNA-291, miRNA-294, and miRNA-295 reduced the number of cells in G1 to that typically found in wild-type ESCs[86] by specifically targeting p21[86] and retinoblastoma-like 2 protein.[87,88] MiRNA-291-3p, miRNA-294, and miRNA-295 are potentially downstream effectors of cMyc and act as a substitute for this transcription factor. The reprogramming efficiency of Oct4, Sox2, and Klf4 was increased by miRNA-291-3p, miRNA-294, and miRNA-295 or cMyc. However, there was no additive effect when the miRNAs and cMyc were used together.[89] Similarly, the human orthologs hsa-miRNA-372 and hsa-miRNA-302b promoted reprogramming in human foreskin and lung fibroblasts, expressing OKSM.[82] Members of the let-7 miRNA family, which are highly expressed in somatic cells, oppose the effects of miRNAs involved in ESC proliferation.[90] Knockdown of let-7 miRNA by an antisense RNA inhibitor promoted the dedifferentiation of murine embryonic fibroblasts (MEFs) to iPS when OKSM were overexpressed.[90] Inactivation of miRNA targets of the cell cycle inhibitor p53 also enhances reprogramming efficiency. MiRNA-199a-3p is upregulated by p53 at the post-transcriptional level; induction of this miRNA significantly decreases reprogramming efficiency by arresting cells in G1. Moreover, miRNA-199a-3p inhibition partially rescues iPS generation impaired by p53.[91] The expression of the miRNA-34 family is also p53-dependent.[92] MiRNA-34a, a member of the miRNA-34 family, restrains iPS reprogramming by acting in concert with p21 to suppress expression of Nanog, Sox2, and N-Myc.[93] The expression of p53 is controlled by miRNAs, and this information has been used to augment reprogramming efficiency. For example, miRNA-138 enhances reprogramming to iPS by binding to the 3′ untranslated region of p53 and decreasing the expression of the protein.[94] Moreover, depletion of 2 MEF-enriched miRNAs, miRNA-21 and miRNA-29a, enhances reprogramming efficiency in part through reduced p53 expression.[95]

MiRNAs also influence the mesenchymal-to-epithelial transition that occurs in the initiation stage of reprogramming by

modulating the transforming growth factor (TGF)-β signaling pathway. The TGF-β receptor-2 protein is a specific target of 2 miRNA clusters, miRNA-106b/25 and miRNA-302/367. Overexpression of the miRNA-302/367 cluster[96,97] or 2 components of miRNA-106b/25 cluster, miRNA-93 and miRNA-106b,[98] accelerates the mesenchymal-to-epithelial transition and increases the number of iPS cells derived from MEFs expressing OKSM or OKS. The miRNA-302/367 cluster (miRNA-302a/b/c/d and miRNA-367), in addition to its role in regulating TGF-β signaling, targets the bone morphogenetic protein inhibitors TOB2, DAZAP2, and SLAIN1.[99] The bone morphogenetic protein and TGF-β signaling pathways converge on Smad proteins, suggesting that miRNA-302/367 could potentially promote reprogramming via these proteins. Cross-talk between TGF-β and cell proliferation pathways also exists. One study, using a library screen, found that the miRNA-130/301/721 family promoted generation of iPS cells by inhibiting expression of mesenchyme homeobox 2.[100] TGF-β suppresses endothelial cell growth through activation of mesenchyme homeobox 2, which in turn triggers expression of p21.[101]

Chromatin remodeling influences the ability of miRNAs to reprogram somatic cells into iPS. Considerable epigenetic changes occur during reprogramming,[102] and pharmacological inhibition of key chromatin modifiers, such as histone deacetylases and DNA methyltransferases, increase the efficiency of reprogramming.[103,104] Histone deacetylase 2 suppression by valproic acid or genetic ablation allows the miRNA-302/367 cluster, a direct target of Oct4 and Sox2,[105] to reprogram MEFs into iPS cells without the need for transcription factors.[81] Similarly, human foreskin fibroblasts which naturally express low levels of histone deacetylase 2 were reprogrammed to iPS by expression of the miRNA-302/367 cluster in the absence of valproic acid.[81] Elevating the expression of a single miRNA, miRNA-302, to a level 1.3-fold above that found in human ESCs was sufficient to reprogram human hair follicle cells to iPS.[106] MiRNA-302 reprogramming to iPS required the repression of several epigenetic regulators, such as the lysine-specific demethylases AOF1 and AOF2, as well as the methyl-CpG-binding proteins MECP1-p66 and MECP2.[106] Apoptosis and senescence have also been proposed as possible mechanisms by which miRNAs regulate reprogramming to iPS; however, definitive roles have not been currently established.[107] Moreover, direct regulation of the OKSM factors is another putative mechanism. MiRNA-25 directly regulates Wwp2, an E3 ubiquitin ligase that targets Oct4 for ubiquitination, and Fbxw7, which is known to regulate c-Myc. By increasing levels of Oct4 and c-Myc, miRNA-25 was found to promote the formation of iPS cells.[108]

To summarize, miRNAs are important tools for reprogramming somatic cells to iPS cells. However, the similarity between miRNA and transcription factor reprogrammed iPS has not been studied and differences may exist in the iPS generated by the 2 methods.

MiRNAs, iPS, ESCs, and the Acquisition of a Cardiac Phenotype

Several microRNAs, including miRNA-1, miRNA-133, miRNA-208, and miRNA-499, have also been used to drive cardiac differentiation in ESCs and IPS cells.[109,110]

In a 2D ESC culture model, levels of miRNA-1 and miRNA-133 were reduced following forced myocardial differentiation by trichostatin-A, a histone deacetylase inhibitor.[111] Moreover, overexpression of miRNA-1 or miRNA-133 by lentivirus reduced the expression of Nkx2.5, with miRNA-1 also inhibiting expression of αMHC. CDK9 was proposed to be involved in the pathway based on the finding that miRNA-1 reduced protein expression by targeting the 3′ untranslated region of the CDK9 mRNA,[111] as well as previous work by the authors, which showed that CDK9 formed a transcriptional complex with p300/Gata4 to activate expression of Nkx2.5, ANF, and β-MHC.[112] In support of these studies, overexpression of the drosophila miRNA-1 homolog in cardiac mesoderm resulted in fewer cardiac cells.[113]

However, the effects of miRNA-1 and miRNA-133 on ESC cardiac differentiation may be dependent on the model used because the findings with embryoid body–based culture of ESC cells were found to be markedly different.[109] Starting from the observation that both miRNA-1 and miRNA-133 were highly expressed in ESC-derived cardiomyocytes, the authors found that expression of miRNA-1 or miRNA-133 in embryoid body promoted mesoderm gene expression at the expense of ectoderm and endoderm differentiation. Moreover, although miRNA-1 promoted further differentiation toward a cardiac or skeletal muscle fate, miRNA-133 was inhibitory. The Notch ligand, delta-like 1, was translationally repressed by miRNA-1, and indeed knockdown of delta-like 1 recapitulated the miRNA-1 overexpression phenotype in ESCs.[109] Further support for a role of miRNA-1 in the adoption of a cardiomyocyte phenotype has come from studies in Xenopus embryos.[42] Misexpression of miRNA-1 strongly inhibited myogenesis by targeting histone deacetylase 4,[42] which negatively regulates a protein critical for muscle differentiation, Mef2.[114] Moreover, overexpression of miRNA-1 in iPS cells led to the expression of cardiac transcription factors and sarcomeric proteins.[115] Similarly, in ESC-derived multipotent cardiovascular progenitors, miRNA-1 promoted cardiomyocyte differentiation and suppressed endothelial cell commitment by modulating Wnt and FGF signaling pathways, with frizzled class receptor 7 and far1-related sequence being confirmed as miRNA-1 targets.[115]

MiRNA-1 may also be involved in the electrophysiological maturation of ESC-derived cardiomyocytes.[116] Lentiviral-mediated delivery of miRNA-1 into human ESC-derived cardiovascular progenitors had no effect on the yield of human ESC-derived ventricular cadiomyocytes. However, hallmarks of maturation were observed, such as decreased action potential duration and hyperpolarized resting membrane potential/maximum diastolic potential. Ca^{2+} transient amplitude and kinetics were also augmented.[116]

Irrespective of the in vitro results, overexpression of miRNA-1 has been shown to drive cardiac differentiation of ESCs in vivo.[117] When assessed 2 weeks post-MI, injected ESCs expressing miRNA-1 demonstrated enhanced commitment to the cardiomyocyte lineage when compared with control ESCs, and improved cardiac function was noted.[117] A paracrine mechanism may also be important in this model because the host myocardium displayed reduced apoptosis through Akt activation and caspase-3 inactivation.[117]

Levels of miRNA-499 also increase during the differentiation of ESC cells into cardiomyocytes.[110] Overexpression of miRNA-499 in embryoid bodies upregulated αMHC and Mef2C expression.[110] Similarly increasing expression of miRNA-499 in human ESC-derived cardiovascular progenitors significantly augmented the yield of ventricular cardiomyocytes and contractile protein expression without affecting electrophysiological properties.[116]

MiRNA-363 is involved in ESC-derived cardiac subtype specification. Screening for miRNAs that potentially affected Hand1 and 2, genes involved in left and right ventricular development respectively, identified miRNA-363 as a candidate. Over-expression of miRNA-363 reduced Hand1 mRNA levels, and suppression of this miRNA led to an enrichment of left ventricular ESC-derived cardiomyocytes.[118]

MiRNAs and Direct Cardiac Reprogramming

Development of MiRNA Combo for the Transdifferentiation of Fibroblasts to Cardiomyocytes

Based on their roles in cardiac development, our laboratory hypothesized that miRNAs would be capable of reprogramming fibroblasts directly into cardiomyocytes.[9] We selected 6 candidate miRNAs, miRNA-1, miRNA-126, miRNA-133a, miRNA-138, miRNA-206, and miRNA-208a, based on their function in cardiac muscle development and differentiation.[40,47,55,119–121] Adopting a combinatorial approach, we identified that miRNA-1 and the combination of miRNA-1, miRNA-133a, and miRNA-208a induced the expression of early markers of commitment to the cardiomyocyte lineage.[9] Though miRNA-1 alone was found to be sufficient to drive cardiac gene expression, efficiency was higher in combination with miRNA-133a and miRNA-208a. Further studies showed that the addition of miRNA-499 further augmented the efficiency of cardiac reprogramming.[9] This combination of miRNAs, miRNA-1, miRNA-133a, miRNA-208a, and miRNA 499, we named miR combo. A single transient transfection of miR combo was found to be sufficient to induce fibroblasts to express cardiac markers, such as Mef2C and αMHC.[9,10] The initial steps of reprogramming were relatively rapid in vitro. Mature cardiomyocyte markers, such as αMHC and cardiac troponins, were observed ≈7 days after transfection. Full maturation of the reprogrammed cells was observed only after prolonged culture. Approximately 4 weeks after transfection, organized sarcomeres, contraction, and spontaneous calcium transients were observed.[9]

miR Combo Regenerates the Heart: Reprogramming and the Correlation Between Maturation and Functional Improvement

In a proof-of-principle experiment, we used the Fsp1Cre:tdTomato (tandem dimer Tomato) model to validate reprogramming of fibroblasts in vivo. In this model, the td-Tomato protein permanently labels fibroblasts. Lentiviruses encoding for the individual miRNAs in the miR combo were injected into ischemic myocardium. One month after myocardial injury, tdTomato+cardiomyocytes were observed, which provided evidence of direct reprogramming of fibroblasts in situ.[9] We found that 1 month post-MI, tdTomato+cardiomyocytes

represented ≈1% of the infarct border zone, and 2 months post-MI, the number of tdTomato+cardiomyocytes had risen to ≈10%.[9,11] We observed that miR combo promoted a progressive improvement in cardiac function over a 3-month period associated with reduced fibrosis after MI.[11] The improvement of cardiac function by miR combo occurred in the absence of any effects on cardiomyocyte apoptosis and de novo vascularization. Thus, the effect of miR combo in vivo on cardiac function was both progressive and time-delayed. This has also been observed with reprogramming strategies involving transcription factors. Based on our in vitro observation of time taken from reprogramming to cell maturation, we hypothesized that the delay in cardiac functional improvement in vivo is in part as a result of the time taken for reprogrammed fibroblasts to fully mature into cardiomyocytes and integrate into the myocardium. Indeed, at 2 months, the reprogrammed tdTomato+cardiomyocytes expressed cardiomyocyte markers, sarcomeric organization, excitation–contraction coupling, and action potentials characteristic of maturing ventricular tdTomato–cardiomyocytes.[11] Taken together, our findings suggest a correlation between maturation of reprogrammed cardiomyocytes and improved cardiac function (Figure 1A). Fully establishing that full maturation of reprogrammed fibroblasts into cardiomyocytes underlies the improvements in cardiac function will require a systematic study of the temporal effects of miR combo treatment at the cellular and functional level in conjunction with statistical modeling.

Maturation: Why Is There More In Vivo?

Reprogramming with miR combo is more efficient in vivo than in vitro. Why this is the case is currently unknown. It is possible that other cell types in the heart, cardiomyocytes and cardiac progenitor cells, influence reprogramming either through the release of paracrine factors or by cell:cell communication through adherens junctions. We anticipate that paracrine factors will play a particularly important role. In the past decade, substantial evidence has been provided to support the notion that stem cells exert their reparative and regenerative effects, in large part, through the release of biologically active molecules acting in a paracrine fashion on resident cells.[122] Pertinent to this review, we have recently identified that a paracrine factor released by mesenchymal stem cells, Abi3bp, promotes cardiac progenitor cell differentiation.[123]

Tissue engineers have sought to recapitulate the native cardiac environment. They have had notable successes in generating cardiac tissue,[124] and their findings potentially shed light on the question of why maturation of miR combo–reprogrammed fibroblasts is more efficient in vivo. What they have found is that 3D environments, decellularization of organs which leaves extracellular matrix intact, and stimulation, whether it be mechanical or electric, promote the formation of cardiac tissue.[124] Thus, we hypothesize that components of the extracellular matrix, mechanical forces, and the cell shape in the 3D environment is important (Figure 1B) for the maturation of miR combo reprogrammed cells. These mechanisms would promote maturation either by increasing the rate of the initial reprogramming event or by directly affecting the expression of mature cardiac structural and functional proteins.

Figure 1. Schematic describing the hypothesis that the time-delayed improvements in cardiac function are dependent on the maturation of reprogrammed cells. **A**,The cardiac function data (fractional shortening) vs time are derived from Jayawardena et al.[11] The **upper panel** depicting the progression of transdifferentiation (with specific cardiac gene expression) to maturation is based partly on data[11] and partly on hypothesis. **B**, The putative factors influencing cardiomyocyte maturation in vivo: paracrine factors released by other cardiac cells, the composition of the ECM, mechanical forces and cell:cell communication. Mef2 indicates myocyte enhancer factor; MHC, myosin heavy chain; and miR, microRNA.

Mechanisms for Direct Reprogramming of Cardiac Fibroblasts by miR Combo

Knowledge of the mechanistic basis for the reprogramming of cardiac fibroblasts into cardiomyocytes by transcription factors or miRNAs is currently lacking. The epigenetic landscape of cardiac fibroblasts is likely to be different to that of cardiomyocytes; such differences are believed to be important for the maintenance of a differentiated phenotype.[125] Differences between the epigenetic landscape of cardiac fibroblasts and cardiomyocytes would be expected to be a significant barrier to direct reprogramming.[125] The transcription factors currently used, such as Mef2C, Gata4, and Tbx5 (GMT), are known to be important for the development of heart. However, how these transcription factors access the silent promoters of

cardiac genes in fibroblasts is currently unknown; presumably they act as pioneer transcription factors that recognize their target sites irrespective of the preexisting chromatin state. Considering that the epigenetic landscape represents a molecular roadblock to reprogramming,[125] we conducted a genetic screen to identify epigenetic modifiers regulated by miR combo. We found that miRNA combo downregulates expression of the histone lysine *N*-methyltransferase Setdb2, a protein which specifically trimethylates lysine-9 of histone H3. Considering that trimethylates lysine-9 of histone H3 is associated with transcriptional repression, our data indicates that miR combo induces reprogramming by alleviating the suppression of cardiac genes in fibroblasts (unpublished data). Future work is necessary to determine which constituent of


Figure 2. MicroRNAs (miRNAs/miR) and reprogramming. miRNAs promote the generation of cardiomyocytes via several mechanisms. Fibroblasts (FB) can be reprogrammed into cardiomyocytes (CM) by miRNAs directly or through an intermediate inducible pluripotent stem (iPSC) state. miRNAs also promote cardiac progenitor cell (CPC) and embryonic stem cell (ESC) cardiac differentiation. miRNAs can promote or inhibit cardiomycyte proliferation.

miR combo downregulates Setdb2 expression, as well as the possible role of other epigenetic modifications in mediating the effects of miR combo.

Enhancing Direct Reprogramming by Combining miRNA and Transcription Factor Strategies

Other researchers have used miRNA-1 and miRNA-133 in combination with transcription factors to increase the efficiency of mouse and human fibroblast reprogramming into cardiomyocytes in vitro. Nam et al were able to drive expression of cardiac markers in neonatal and human fibroblasts using miRNA-1, miRNA-133, Gata4, Hand2, Tbx5, and myocardin. Four to 11 weeks after transfection, sarcomeric-like structures and calcium transients were observed, with several cells showing spontaneous contractility.[126] Gata4, Hand2, Tbx5, myocardin, and Mef2C were originally identified as being able to reprogram fibroblasts into cardiomyocytes. Retroviral expression of miRNA-1 and miRNA-133 increased the number of cardiac troponin-T-positive cells. Curiously, removal of Mef2C enhanced reprogramming.[126] Underlying the importance of miRNA-133, genetic ablation of this miRNA reduced the number of cardiac troponin-T-positive cells to almost background levels.[126] The authors speculated that miRNA-1 and miRNA-133 were important for the development of sarcomeres and suppressed myocardin activation of smooth muscle differentiation.[126] miRNA-133, in combination with GMT, has also been shown to be important in the acquisition of a cardiac phenotype in MEFs.[127] Overexpression of miRNA-133, in combination with GMT, increased by >5-fold the number of MEFs expressing α-sarcomeric actinin, αMHC, and cardiac troponin-T when compared with cells expressing GMT alone. Similar results were obtained with the number of beating cells, and the time taken for maturation was found to be significantly shortened.[127] The authors showed that miRNA-133 enhanced GMT reprogramming by silencing fibroblast markers via suppression of the epithelial-to-mesenchymal transition regulator Snai1.[127]

MiRNAs and Adult Cardiac Stem Cells

The heart contains resident cardiac progenitors, which can potentially form all the major cell types of the heart, including cardiomyocytes, endothelial cells, and smooth muscle.[128] In 2 recent clinical trials, SCIPIO and CADUCEUS, cardiac progenitor cells have demonstrated their therapeutic potential.[129,130] Strategies are needed to drive cardiac progenitor differentiation toward the cardiomyocyte lineage, especially because currently this is inefficient. Despite the potential benefits of miRNAs to direct cardiac progenitor fate, a relatively limited number of reports have been published regarding their use in this regard.

Transient transfection of miRNA-1 and miRNA-499 into cardiac progenitors derived from human fetuses reduced cell proliferation and enhanced differentiation to cardiomyocytes; for example, reducing the time taken for spontaneously beating clusters to appear from 21 to 7 days.[131] The effects of miRNA-1 and miRNA-499 were likely as a result of the repression of histone deacetylase 4 or Sox6. Indeed, siRNA mediated knockdown of Sox6-induced cardiomyocyte differentiation.[131]

The results with miRNA-499 were confirmed by a separate study using c-Kit+ cardiac progenitors.[132] Here, the authors went one step further and injected cardiac progenitors expressing miRNA-499 into infarcted hearts. Increased cardiomyogenesis was observed with an elevated cardiomyocyte mass.[132] The authors also identified a novel mechanism by which miRNA-499 can influence cardiac progenitor behavior. MiRNA-499 was found to translocate from C2C12 myoblasts to recipient cardiac progenitor cells via gap junctions between the 2 cell types. The function of the miRNA-499 was preserved after gap junction transfer to cardiac progenitors, and this favored their differentiation into functionally competent cardiomyocytes.[132] MiRNA-1 is also important for the control of cardiac progenitor cell polarity during development in drosophila.[133] Cell polarity is known to play multiple roles in cardiac differentiation and development.[134] MiRNAs are also involved in inhibiting differentiation. For example, miRNA-590 and miRNA-155 have opposing effects on cardiac progenitor differentiation. TGF-β1 promotes differentiation of cardiosphere-derived cells by the downregulation of miRNA-590.[135] MiRNA-155 inhibits Sca-1+ cardiac progenitor cell differentiation by downregulating β-arrestin-2.[136]

Differentiation of cardiac progenitors requires a halt in proliferation. Sirish et al compared miRNA expression profiles in c-Kit+ cardiac progenitors derived from neonatal and adult hearts. When compared with adult cells, neonatal c-Kit+ cardiac progenitors expressed higher levels of the proliferation marker Ki67 with a 7-fold higher doubling time. MiRNA-17 was also elevated in neonatal c-Kit+ cardiac progenitors, and as a proof-of-principle expression of the miRNA-17-92 cluster in adult, c-Kit+ progenitors increased their proliferation rate. The antiproliferative cell cycle protein retinoblastoma-like 2 (Rbl2/p130) was proposed as a target for miRNA-17 on the basis of an interaction site within the 3′ untranslated region; though Rbl2/p130 mRNA levels were not significantly different, protein levels were significantly lower in neonatal c-Kit+ cardiac progenitor cells when compared with adult cells.[137] MiRNA-10a reduces cardiac progenitor cell proliferation by targeting Gata6.[138]

In summary, several microRNAs have been identified that regulate key aspects of cardiac progenitor biology. However, it is clear that more studies are necessary to fully characterize the full complement of microRNAs that influence cardiac progenitor differentiation and proliferation.

Future Perspectives

The studies described in this review highlight the fundamental role that miRNAs play in cardiac reprogramming, differentiation, and development (Figure 2). Based on the understanding of above, we hypothesize that targeting specific miRNAs is a rational strategy for cardiac regenerative therapy.

MiRNA-based therapy can be used to promote cardiomyocyte proliferation, reprogram directly fibroblasts to cardiomyocytes or indirectly to iPSc, as well as driving the differentiation of iPSCs, ESCs, or CPCs to cardiomyocytes (Figure 2).

Key issues need to be addressed before miRNAs can be taken into the clinic. One such question is the combination of miRNAs that will induce cardiac regeneration. Species

differences between mouse and human are likely to necessitate a different combination of miRNAs for efficient proliferation and direct or indirect reprogramming.[127] Another question is how these miRNAs will be delivered into the patient. There are several options, such as viral delivery or chemical modification. Lenti-, retro-, and adenoviral-associated viruses are all suitable viral delivery systems each with their own specific advantages and disadvantages.[139,140] The adenoviral-associated virus approach is potentially the most suitable because adenoviral-associated viruses offer significant benefits over lenti- and retro-viruses, such as nonintegration, into the host genome.[141,142] A single virus containing all of the reprogramming factors is the obvious ideal approach, and this further highlights the benefits of miRNAs as a reprogramming strategy over transcription factors. Only a limited amount of DNA can be packaged into a virus, and miRNAs are smaller DNA moieties than transcription factor genes. Currently, the in vivo use of transcription factors for reprogramming has relied on retroviruses containing a single transcription factor.[7] Another potential issue is the expression of multiple genes from a single DNA cassette; the genes do not necessarily express at similar levels,[143] and this could seriously affect reprogramming efficiency. Naturally occurring multicistronic miRNA constructs can be modified to express any miRNA combination of choice. For example, modification of the endogenous miR-NA-17-92 cluster to express miRNAs that target the hepatitis C viral genome prevents replication of the hepatitis C virus.[139] This has been used to inhibit hepatitis C virus replication, for example, by modifying packaging DNA into viral vectors because of their small size.

AntagomiRs, miRNAs modified with cholesterol or phosphorothioate moieties to increase their stability in vivo,[140] have been used to reduce the expression of miRNAs that mediate pathology after myocardial injury.[144] AntagomiRs may also prove to be a useful ally for cardiac reprogramming. It is well known that there are significant barriers to reprogramming.[125] Cell type–specific miRNAs prevent translation of lineage-inappropriate mRNAs.[125,145] Targeting these cell type–specific miRNAs with antagomiRs is likely to enhance cardiac reprogramming.

Cardiomyocyte proliferation, differentiation, and reprogramming involve the co-ordinated action of many proteins acting in multiple pathways. For this reason, of all the many strategies used for reprogramming, miRNAs offer the most appropriate route because a single miRNA can influence multiple pathways at once. By virtue of their small size, miRNAs are ideal for adenoviral-associated virus–based therapies, which have generated much interest because of their inherent safety. Finally, by adapting naturally occurring multicistronic miRNA constructs, researchers have the ability to nuance the expression of reprogramming miRNAs, which is important for dosing concerns.

Sources of Funding

Disclosures

None.

References

1. Fan D, Takawale A, Lee J, Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. *Fibrogenesis Tissue Repair*. 2012;5:15. doi: 10.1186/1755-1536-5-15.

2. Dal-Pra S, Mirotsou M. Reprogramming approaches in cardiovascular regeneration. *Curr Treat Options Cardiovasc Med*. 2014;16:327. doi: 10.1007/s11936-014-0327-0.

3. Buckingham M, Meilhac S, Zaffran S. Building the mammalian heart from two sources of myocardial cells. *Nat Rev Genet*. 2005;6:826–835. doi: 10.1038/nrg1710.

4. Olson EN. Gene regulatory networks in the evolution and development of the heart. *Science*. 2006;313:1922–1927. doi: 10.1126/science.1132292.

5. Srivastava D. Making or breaking the heart: from lineage determination to morphogenesis. *Cell*. 2006;126:1037–1048. doi: 10.1016/j.cell.2006.09.003.

6. Song K, Nam YJ, Luo X, Qi X, Tan W, Huang GN, Acharya A, Smith CL, Tallquist MD, Neilson EG, Hill JA, Bassel-Duby R, Olson EN. Heart repair by reprogramming non-myocytes with cardiac transcription factors. *Nature*. 2012;485:599–604. doi: 10.1038/nature11139.

7. Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L, Conway SJ, Fu JD, Srivastava D. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. *Nature*. 2012;485:593–598. doi: 10.1038/nature11044.

8. Protze S, Khattak S, Poulet C, Lindemann D, Tanaka EM, Ravens U. A new approach to transcription factor screening for reprogramming of fibroblasts to cardiomyocyte-like cells. *J Mol Cell Cardiol*. 2012;53:323–332. doi: 10.1016/j.yjmcc.2012.04.010.

9. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, Pandya K, Zhang Z, Rosenberg P, Mirotsou M, Dzau VJ. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. *Circ Res*. 2012;110:1465–1473. doi: 10.1161/CIRCRESAHA.112.269035.

10. Jayawardena T, Mirotsou M, Dzau VJ. Direct reprogramming of cardiac fibroblasts to cardiomyocytes using microRNAs. *Methods Mol Biol*. 2014;1150:263–272. doi: 10.1007/978-1-4939-0512-6_18.

11. Jayawardena TM, Finch EA, Zhang L, Zhang H, Hodgkinson CP, Pratt RE, Rosenberg PB, Mirotsou M, Dzau VJ. MicroRNA induced cardiac reprogramming in vivo: evidence for mature cardiac myocytes and improved cardiac function. *Circ Res*. 2015;116:418–424. doi: 10.1161/CIRCRESAHA.116.304510.

12. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. *Nat Rev Genet*. 2009;10:94–108. doi: 10.1038/nrg2504.

13. Schraivogel D, Meister G. Import routes and nuclear functions of Argonaute and other small RNA-silencing proteins. *Trends Biochem Sci*. 2014;39:420–431. doi: 10.1016/j.tibs.2014.07.004.

14. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. *Nucleic Acids Res*. 2014;42:D68–D73. doi: 10.1093/nar/gkt1181.

15. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res*. 2009;19:92–105. doi: 10.1101/gr.082701.108.

16. Ha M, Kim VN. Regulation of microRNA biogenesis. *Nat Rev Mol Cell Biol*. 2014;15:509–524. doi: 10.1038/nrm3838.

17. Coolen M, Bally-Cuif L. MicroRNAs in brain development and physiology. *Curr Opin Neurobiol*. 2009;19:461–470. doi: 10.1016/j.conb.2009.09.006.

18. Malizia AP, Wang DZ. MicroRNAs in cardiomyocyte development. *Wiley Interdiscip Rev Syst Biol Med*. 2011;3:183–190. doi: 10.1002/wsbm.111.

19. Ambros V. MicroRNAs and developmental timing. *Curr Opin Genet Dev*. 2011;21:511–517. doi: 10.1016/j.gde.2011.04.003.

20. Vidigal JA, Ventura A. Embryonic stem cell miRNAs and their roles in development and disease. *Semin Cancer Biol*. 2012;22:428–436. doi: 10.1016/j.semcancer.2012.04.009.

21. Sokol NS. Small temporal RNAs in animal development. *Curr Opin Genet Dev*. 2012;22:368–373. doi: 10.1016/j.gde.2012.04.001.

22. Kuppusamy KT, Sperber H, Ruohola-Baker H. MicroRNA regulation and role in stem cell maintenance, cardiac differentiation and hypertrophy. *Curr Mol Med*. 2013;13:757–764.

23. Wang XH. MicroRNA in myogenesis and muscle atrophy. *Curr Opin Clin Nutr Metab Care*. 2013;16:258–266. doi: 10.1097/MCO.0b013e32835f81b9.

24. Sun AX, Crabtree GR, Yoo AS. MicroRNAs: regulators of neuronal fate. *Curr Opin Cell Biol*. 2013;25:215–221. doi: 10.1016/j.ceb.2012.12.007.

25. Luo W, Nie Q, Zhang X. MicroRNAs involved in skeletal muscle differentiation. *J Genet Genomics*. 2013;40:107–116. doi: 10.1016/j.jgg.2013.02.002.

26. Cremisi F. MicroRNAs and cell fate in cortical and retinal development. *Front Cell Neurosci*. 2013;7:141. doi: 10.3389/fncel.2013.00141.

27. Turner ML, Schnorfeil FM, Brocker T. MicroRNAs regulate dendritic cell differentiation and function. *J Immunol*. 2011;187:3911–3917. doi: 10.4049/jimmunol.1101137.

28. Rao PK, Kumar RM, Farkhondeh M, Baskerville S, Lodish HF. Myogenic factors that regulate expression of muscle-specific microRNAs. *Proc Natl Acad Sci U S A*. 2006;103:8721–8726. doi: 10.1073/pnas.0602831103.

29. Takaya T, Nishi H, Horie T, Ono K, Hasegawa K. Roles of microRNAs and myocardial cell differentiation. *Prog Mol Biol Transl Sci*. 2012;111:139–152. doi: 10.1016/B978-0-12-398459-3.00006-X.

30. Joladarashi D, Thandavarayan RA, Babu SS, Krishnamurthy P. Small engine, big power: microRNAs as regulators of cardiac diseases and regeneration. *Int J Mol Sci*. 2014;15:15891–15911. doi: 10.3390/ijms150915891.

31. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. *RNA*. 2004;10:1957–1966. doi: 10.1261/rna.7135204.

32. Gommans WM, Berezikov E. Controlling miRNA regulation in disease. *Methods Mol Biol*. 2012;822:1–18. doi: 10.1007/978-1-61779-427-8_1.

33. Ogata H, Audic S, Renesto-Audiffren P, Fournier PE, Barbe V, Samson D, Roux V, Cossart P, Weissenbach J, Claverie JM, Raoult D. Mechanisms of evolution in Rickettsia conorii and R. prowazekii. *Science*. 2001;293:2093–2098. doi: 10.1126/science.1061471.

34. Azuma-Mukai A, Oguri H, Mituyama T, Qian ZR, Asai K, Siomi H, Siomi MC. Characterization of endogenous human Argonautes and their miRNA partners in RNA silencing. *Proc Natl Acad Sci U S A*. 2008;105:7964–7969. doi: 10.1073/pnas.0800334105.

35. Iwasaki S, Kobayashi M, Yoda M, Sakaguchi Y, Katsuma S, Suzuki T, Tomari Y. Hsc70/Hsp90 chaperone machinery mediates ATP-dependent RISC loading of small RNA duplexes. *Mol Cell*. 2010;39:292–299. doi: 10.1016/j.molcel.2010.05.015.

36. Kawamata T, Seitz H, Tomari Y. Structural determinants of miRNAs for RISC loading and slicer-independent unwinding. *Nat Struct Mol Biol*. 2009;16:953–960. doi: 10.1038/nsmb.1630.

37. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Hammond SM, Schneider MD, Selzman CH, Meissner G, Patterson C, Hannon GJ, Wang DZ. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. *Proc Natl Acad Sci U S A*. 2008;105:2111–2116. doi: 10.1073/pnas.0710228105.

38. da Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM, Molkentin JD, De Windt LJ. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. *Circulation*. 2008;118:1567–1576. doi: 10.1161/CIRCULATIONAHA.108.769984.

39. Saxena A, Tabin CJ. miRNA-processing enzyme Dicer is necessary for cardiac outflow tract alignment and chamber septation. *Proc Natl Acad Sci U S A*. 2010;107:87–91. doi: 10.1073/pnas.0912870107.

40. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. *Cell*. 2007;129:303–317. doi: 10.1016/j.cell.2007.03.030.

41. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. *Nature*. 2005;436:214–220. doi: 10.1038/nature03817.

42. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. *Nat Genet*. 2006;38:228–233. doi: 10.1038/ng1725.

43. Liu N, Williams AH, Kim Y, McAnally J, Bezprozvannaya S, Sutherland LB, Richardson JA, Bassel-Duby R, Olson EN. An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. *Proc Natl Acad Sci U S A*. 2007;104:20844–20849. doi: 10.1073/pnas.0710558105.

44. Heidersbach A, Saxby C, Carver-Moore K, Huang Y, Ang YS, de Jong PJ, Ivey KN, Srivastava D. microRNA-1 regulates sarcomere formation and suppresses smooth muscle gene expression in the mammalian heart. *Elife*. 2013;2:e01323. doi: 10.7554/eLife.01323.

45. Wei Y, Peng S, Wu M, Sachidanandam R, Tu Z, Zhang S, Falce C, Sobie EA, Lebeche D, Zhao Y. Multifaceted roles of miR-1s in repressing the fetal gene program in the heart. *Cell Res*. 2014;24:278–292. doi: 10.1038/cr.2014.12.

46. Yin VP, Lepilina A, Smith A, Poss KD. Regulation of zebrafish heart regeneration by miR-133. *Dev Biol*. 2012;365:319–327. doi: 10.1016/j.ydbio.2012.02.018.

47. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R, Olson EN. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. *Genes Dev*. 2008;22:3242–3254. doi: 10.1101/gad.1738708.

48. Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. *Nat Med*. 2007;13:613–618. doi: 10.1038/nm1582.

49. Li Q, Lin X, Yang X, Chang J. NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression. *Am J Physiol Heart Circ Physiol*. 2010;298:H1340–H1347. doi: 10.1152/ajpheart.00592.2009.

50. Dong DL, Chen C, Huo R, Wang N, Li Z, Tu YJ, Hu JT, Chu X, Huang W, Yang BF. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. *Hypertension*. 2010;55:946–952. doi: 10.1161/HYPERTENSIONAHA.109.139519.

51. Wystub K, Besser J, Bachmann A, Boettger T, Braun T. miR-1/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of myocardin levels during embryonic heart development. *PLoS Genet*. 2013;9:e1003793. doi: 10.1371/journal.pgen.1003793.

52. Lompré AM, Nadal-Ginard B, Mahdavi V. Expression of the cardiac ventricular alpha- and beta-myosin heavy chain genes is developmentally and hormonally regulated. *J Biol Chem*. 1984;259:6437–6446.

53. Chien KR. Genomic circuits and the integrative biology of cardiac diseases. *Nature*. 2000;407:227–232. doi: 10.1038/35025196.

54. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. *Science*. 2007;316:575–579. doi: 10.1126/science.1139089.

55. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, Willis MS, Selzman CH, Wang DZ. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. *J Clin Invest*. 2009;119:2772–2786. doi: 10.1172/JCI36154.

56. van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, Richardson JA, Kelm RJ Jr, Olson EN. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. *Dev Cell*. 2009;17:662–673. doi: 10.1016/j.devcel.2009.10.013.

57. Morkin E. Control of cardiac myosin heavy chain gene expression. *Microsc Res Tech*. 2000;50:522–531.

58. Shieh JT, Huang Y, Gilmore J, Srivastava D. Elevated miR-499 levels blunt the cardiac stress response. *PLoS One*. 2011;6:e19481. doi: 10.1371/journal.pone.0019481.

59. Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn GW II. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. *Circ Res*. 2012;111:521–531. doi: 10.1161/CIRCRESAHA.112.265736.

60. Laflamme MA, Murry CE. Heart regeneration. *Nature*. 2011;473:326–335. doi: 10.1038/nature10147.

61. Soonpaa MH, Field LJ. Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. *Am J Physiol*. 1997;272:H220–H226.

62. Hodgkinson CP, Dzau VJ. Conserved microRNA program as key to mammalian cardiac regeneration: insights from Zebrafish. *Circ Res*. 2015;116:1109–1111. doi: 10.1161/CIRCRESAHA.115.305852.

63. Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. *Science*. 2002;298:2188–2190. doi: 10.1126/science.1077857.

64. Jopling C, Boue S, Izpisua Belmonte JC. Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. *Nat Rev Mol Cell Biol*. 2011;12:79–89. doi: 10.1038/nrm3043.

65. Aguirre A, Montserrat N, Zacchigna S, et al. In vivo activation of a conserved microRNA program induces mammalian heart regeneration. *Cell Stem Cell*. 2014;15:589–604. doi: 10.1016/j.stem.2014.10.003.

66. Chen J, Huang ZP, Seok HY, Ding J, Kataoka M, Zhang Z, Hu X, Wang G, Lin Z, Wang S, Pu WT, Liao R, Wang DZ. mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. *Circ Res*. 2013;112:1557–1566. doi: 10.1161/CIRCRESAHA.112.300658.

67. Porrello ER, Johnson BA, Aurora AB, Simpson E, Nam YJ, Matkovich SJ, Dorn GW II, van Rooij E, Olson EN. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. *Circ Res*. 2011;109:670–679. doi: 10.1161/CIRCRESAHA.111.248880.

68. Porrello ER, Mahmoud AI, Simpson E, Johnson BA, Grinsfelder D, Canseco D, Mammen PP, Rothermel BA, Olson EN, Sadek HA. Regulation of neonatal and adult mammalian heart regeneration by

the miR-15 family. *Proc Natl Acad Sci U S A*. 2013;110:187–192. doi: 10.1073/pnas.1208863110.

69. Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, Dalby CM, Robinson K, Stack C, Latimer PA, Hare JM, Olson EN, van Rooij E. Inhibition of miR-15 protects against cardiac ischemic injury. *Circ Res*. 2012;110:71–81. doi: 10.1161/CIRCRESAHA.111.244442.

70. Cao X, Wang J, Wang Z, Du J, Yuan X, Huang W, Meng J, Gu H, Nie Y, Ji B, Hu S, Zheng Z. MicroRNA profiling during rat ventricular maturation: A role for miR-29a in regulating cardiomyocyte cell cycle re-entry. *FEBS Lett*. 2013;587:1548–1555. doi: 10.1016/j.febslet.2013.01.075.

71. Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, Giacca M. Functional screening identifies miRNAs inducing cardiac regeneration. *Nature*. 2012;492:376–381. doi: 10.1038/nature11739.

72. Martinez-Fernandez A, Nelson TJ, Yamada S, Reyes S, Alekseev AE, Perez-Terzic C, Ikeda Y, Terzic A. iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. *Circ Res*. 2009;105:648–656. doi: 10.1161/CIRCRESAHA.109.203109.

73. Mauritz C, Schwanke K, Reppel M, Neef S, Katsirntaki K, Maier LS, Nguemo F, Menke S, Haustein M, Hescheler J, Hasenfuss G, Martin U. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. *Circulation*. 2008;118:507–517. doi: 10.1161/CIRCULATIONAHA.108.778795.

74. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. *Circulation*. 2009;120:408–416. doi: 10.1161/CIRCULATIONAHA.109.865154.

75. Priori SG, Napolitano C, Di Pasquale E, Condorelli G. Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. *J Clin Invest*. 2013;123:84–91. doi: 10.1172/JCI62838.

76. Yoshida Y, Yamanaka S. iPS cells: a source of cardiac regeneration. *J Mol Cell Cardiol*. 2011;50:327–332. doi: 10.1016/j.yjmcc.2010.10.026.

77. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006;126:663–676. doi: 10.1016/j.cell.2006.07.024.

78. Hochedlinger K, Plath K. Epigenetic reprogramming and induced pluripotency. *Development*. 2009;136:509–523. doi: 10.1242/dev.020867.

79. Polo JM, Anderssen E, Walsh RM, et al. A molecular roadmap of reprogramming somatic cells into iPS cells. *Cell*. 2012;151:1617–1632. doi: 10.1016/j.cell.2012.11.039.

80. Miyoshi N, Ishii H, Nagano H, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. *Cell Stem Cell*. 2011;8:633–638. doi: 10.1016/j.stem.2011.05.001.

81. Anokye-Danso F, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, Zhang Y, Yang W, Gruber PJ, Epstein JA, Morrisey EE. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. *Cell Stem Cell*. 2011;8:376–388. doi: 10.1016/j.stem.2011.03.001.

82. Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, Derynck R, Blelloch R. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. *Nat Biotechnol*. 2011;29:443–448. doi: 10.1038/nbt.1862.

83. Stead E, White J, Faast R, Conn S, Goldstone S, Rathjen J, Dhingra U, Rathjen P, Walker D, Dalton S. Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities. *Oncogene*. 2002;21:8320–8333. doi: 10.1038/sj.onc.1206015.

84. Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, van Oudenaarden A, Jaenisch R. Direct cell reprogramming is a stochastic process amenable to acceleration. *Nature*. 2009;462:595–601. doi: 10.1038/nature08592.

85. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. *Nature*. 2009;460:1132–1135. doi: 10.1038/nature08235.

86. Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R. Embryonic stem cell-specific microRNAs regulate the G1-S transition and promote rapid proliferation. *Nat Genet*. 2008;40:1478–1483. doi: 10.1038/ng.250.

87. Tian Y, Zhang Y, Hurd L, Hannenhalli S, Liu F, Lu MM, Morrisey EE. Regulation of lung endoderm progenitor cell behavior by miR302/367. *Development*. 2011;138:1235–1245. doi: 10.1242/dev.061762.

88. Benetti R, Gonzalo S, Jaco I, Muñoz P, Gonzalez S, Schoeftner S, Murchison E, Andl T, Chen T, Klatt P, Li E, Serrano M, Millar S, Hannon G, Blasco MA. A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. *Nat Struct Mol Biol*. 2008;15:268–279. doi: 10.1038/nsmb.1399.

89. Judson RL, Babiarz JE, Venere M, Blelloch R. Embryonic stem cell-specific microRNAs promote induced pluripotency. *Nat Biotechnol*. 2009;27:459–461. doi: 10.1038/nbt.1535.

90. Melton C, Judson RL, Blelloch R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. *Nature*. 2010;463:621–626. doi: 10.1038/nature08725.

91. Wang J, He Q, Han C, Gu H, Jin L, Li Q, Mei Y, Wu M. p53-facilitated miR-199a-3p regulates somatic cell reprogramming. *Stem Cells*. 2012;30:1405–1413. doi: 10.1002/stem.1121.

92. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. *Nature*. 2007;447:1130–1134. doi: 10.1038/nature05939.

93. Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, Zhong Y, Kim SY, Bennett MJ, Chen C, Ozturk A, Hicks GG, Hannon GJ, He L. miR-34 miR-NAs provide a barrier for somatic cell reprogramming. *Nat Cell Biol*. 2011;13:1353–1360. doi: 10.1038/ncb2366.

94. Ye D, Wang G, Liu Y, Huang W, Wu M, Zhu S, Jia W, Deng AM, Liu H, Kang J. MiR-138 promotes induced pluripotent stem cell generation through the regulation of the p53 signaling. *Stem Cells*. 2012;30:1645–1654. doi: 10.1002/stem.1149.

95. Yang CS, Li Z, Rana TM. microRNAs modulate iPS cell generation. *RNA*. 2011;17:1451–1460. doi: 10.1261/rna.2664111.

96. Rosa A, Spagnoli FM, Brivanlou AH. The miR-430/427/302 family controls mesendodermal fate specification via species-specific target selection. *Dev Cell*. 2009;16:517–527. doi: 10.1016/j.devcel.2009.02.007.

97. Liao B, Bao X, Liu L, et al. MicroRNA cluster 302-367 enhances somatic cell reprogramming by accelerating a mesenchymal-to-epithelial transition. *J Biol Chem*. 2011;286:17359–17364. doi: 10.1074/jbc.C111.235960.

98. Li Z, Yang CS, Nakashima K, Rana TM. Small RNA-mediated regulation of iPS cell generation. *EMBO J*. 2011;30:823–834. doi: 10.1038/emboj.2011.2.

99. Lipchina I, Elkabetz Y, Hafner M, Sheridan R, Mihailovic A, Tuschl T, Sander C, Studer L, Betel D. Genome-wide identification of microRNA targets in human ES cells reveals a role for miR-302 in modulating BMP response. *Genes Dev*. 2011;25:2173–2186. doi: 10.1101/gad.17221311.

100. Pfaff N, Fiedler J, Holzmann A, Schambach A, Moritz T, Cantz T, Thum T. miRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2. *EMBO Rep*. 2011;12:1153–1159. doi: 10.1038/embor.2011.176.

101. Valcourt U, Thuault S, Pardali K, Heldin CH, Moustakas A. Functional role of Meox2 during the epithelial cytostatic response to TGF-beta. *Mol Oncol*. 2007;1:55–71. doi: 10.1016/j.molonc.2007.02.002.

102. Koche RP, Smith ZD, Adli M, Gu H, Ku M, Gnirke A, Bernstein BE, Meissner A. Reprogramming factor expression initiates widespread targeted chromatin remodeling. *Cell Stem Cell*. 2011;8:96–105. doi: 10.1016/j.stem.2010.12.001.

103. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. *Nat Biotechnol*. 2008;26:795–797. doi: 10.1038/nbt1418.

104. Mikkelsen TS, Hanna J, Zhang X, Ku M, Wernig M, Schorderet P, Bernstein BE, Jaenisch R, Lander ES, Meissner A. Dissecting direct reprogramming through integrative genomic analysis. *Nature*. 2008;454:49–55. doi: 10.1038/nature07056.

105. Card DA, Hebbar PB, Li L, Trotter KW, Komatsu Y, Mishina Y, Archer TK. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. *Mol Cell Biol*. 2008;28:6426–6438. doi: 10.1128/MCB.00359-08.

106. Lin SL, Chang DC, Lin CH, Ying SY, Leu D, Wu DT. Regulation of somatic cell reprogramming through inducible mir-302 expression. *Nucleic Acids Res*. 2011;39:1054–1065. doi: 10.1093/nar/gkq850.

107. Anokye-Danso F, Snitow M, Morrisey EE. How microRNAs facilitate reprogramming to pluripotency. *J Cell Sci*. 2012;125:4179–4187. doi: 10.1242/jcs.095968.

108. Lu D, Davis MP, Abreu-Goodger C, Wang W, Campos LS, Siede J, Vigorito E, Skarnes WC, Dunham I, Enright AJ, Liu P. MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs. *PLoS One*. 2012;7:e40938. doi: 10.1371/journal.pone.0040938.

109. Ivey KN, Muth A, Arnold J, King FW, Yeh RF, Fish JE, Hsiao EC, Schwartz RJ, Conklin BR, Bernstein HS, Srivastava D. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. *Cell Stem Cell*. 2008;2:219–229. doi: 10.1016/j.stem.2008.01.016.

110. Wilson KD, Hu S, Venkatasubrahmanyam S, Fu JD, Sun N, Abilez OJ, Baugh JJ, Jia F, Ghosh Z, Li RA, Butte AJ, Wu JC. Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499. *Circ Cardiovasc Genet*. 2010;3:426–435. doi: 10.1161/CIRCGENETICS.109.934281.

111. Takaya T, Ono K, Kawamura T, Takanabe R, Kaichi S, Morimoto T, Wada H, Kita T, Shimatsu A, Hasegawa K. MicroRNA-1 and MicroRNA-133 in spontaneous myocardial differentiation of mouse embryonic stem cells. *Circ J*. 2009;73:1492–1497.

112. Sunagawa Y, Morimoto T, Takaya T, Kaichi S, Wada H, Kawamura T, Fujita M, Shimatsu A, Kita T, Hasegawa K. Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes. *J Biol Chem*. 2010;285:9556–9568. doi: 10.1074/jbc.M109.070458.

113. Kwon C, Han Z, Olson EN, Srivastava D. MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. *Proc Natl Acad Sci U S A*. 2005;102:18986–18991. doi: 10.1073/pnas.0509535102.

114. Lu J, McKinsey TA, Zhang CL, Olson EN. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. *Mol Cell*. 2000;6:233–244.

115. Lu TY, Lin B, Li Y, Arora A, Han L, Cui C, Coronnello C, Sheng Y, Benos PV, Yang L. Overexpression of microRNA-1 promotes cardiomyocyte commitment from human cardiovascular progenitors via suppressing WNT and FGF signaling pathways. *J Mol Cell Cardiol*. 2013;63:146–154. doi: 10.1016/j.yjmcc.2013.07.019.

116. Fu JD, Rushing SN, Lieu DK, Chan CW, Kong CW, Geng L, Wilson KD, Chiamvimonvat N, Boheler KR, Wu JC, Keller G, Hajjar RJ, Li RA. Distinct roles of microRNA-1 and -499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. *PLoS One*. 2011;6:e27417. doi: 10.1371/journal.pone.0027417.

117. Glass C, Singla DK. MicroRNA-1 transfected embryonic stem cells enhance cardiac myocyte differentiation and inhibit apoptosis by modulating the PTEN/Akt pathway in the infarcted heart. *Am J Physiol Heart Circ Physiol*. 2011;301:H2038–H2049. doi: 10.1152/ajpheart.00271.2011.

118. Wagh V, Pomorski A, Wilschut KJ, Piombo S, Bernstein HS. MicroRNA-363 negatively regulates the left ventricular determining transcription factor HAND1 in human embryonic stem cell-derived cardiomyocytes. *Stem Cell Res Ther*. 2014;5:75. doi: 10.1186/scrt464.

119. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. *Dev Cell*. 2008;15:272–284. doi: 10.1016/j.devcel.2008.07.008.

120. Morton SU, Scherz PJ, Cordes KR, Ivey KN, Stainier DY, Srivastava D. microRNA-138 modulates cardiac patterning during embryonic development. *Proc Natl Acad Sci U S A*. 2008;105:17830–17835. doi: 10.1073/pnas.0804673105.

121. Townley-Tilson WH, Callis TE, Wang D. MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. *Int J Biochem Cell Biol*. 2010;42:1252–1255. doi: 10.1016/j.biocel.2009.03.002.

122. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. *Circ Res*. 2008;103:1204–1219. doi: 10.1161/CIRCRESAHA.108.176826.

123. Hodgkinson CP, Gomez JA, Payne AJ, Zhang L, Wang X, Dal-Pra S, Pratt RE, Dzau VJ. Abi3bp regulates cardiac progenitor cell proliferation and differentiation. *Circ Res*. 2014;115:1007–1016. doi: 10.1161/CIRCRESAHA.115.304216.

124. Georgiadis V, Knight RA, Jayasinghe SN, Stephanou A. Cardiac tissue engineering: renewing the arsenal for the battle against heart disease. *Integr Biol (Camb)*. 2014;6:111–126. doi: 10.1039/c3ib40097b.

125. Vierbuchen T, Wernig M. Molecular roadblocks for cellular reprogramming. *Mol Cell*. 2012;47:827–838. doi: 10.1016/j.molcel.2012.09.008.

126. Nam YJ, Song K, Luo X, Daniel E, Lambeth K, West K, Hill JA, DiMaio JM, Baker LA, Bassel-Duby R, Olson EN. Reprogramming of human fibroblasts toward a cardiac fate. *Proc Natl Acad Sci U S A*. 2013;110:5588–5593. doi: 10.1073/pnas.1301019110.

127. Muraoka N, Yamakawa H, Miyamoto K, et al. MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures. *EMBO J*. 2014;33:1565–1581. doi: 10.15252/embj.201387605.

128. Leri A, Kajstura J, Anversa P. Role of cardiac stem cells in cardiac pathophysiology: a paradigm shift in human myocardial biology. *Circ Res*. 2011;109:941–961. doi: 10.1161/CIRCRESAHA.111.243154.

129. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. *Lancet*. 2011;378:1847–1857. doi: 10.1016/S0140-6736(11)61590-0.

130. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marbán L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. *Lancet*. 2012;379:895–904. doi: 10.1016/S0140-6736(12)60195-0.

131. Sluijter JP, van Mil A, van Vliet P, Metz CH, Liu J, Doevendans PA, Goumans MJ. MicroRNA-1 and -499 regulate differentiation and proliferation in human-derived cardiomyocyte progenitor cells. *Arterioscler Thromb Vasc Biol*. 2010;30:859–868. doi: 10.1161/ATVBAHA.109.197434.

132. Hosoda T, Zheng H, Cabral-da-Silva M, et al. Human cardiac stem cell differentiation is regulated by a mircrine mechanism. *Circulation*. 2011;123:1287–1296. doi: 10.1161/CIRCULATIONAHA.110.982918.

133. King IN, Qian L, Liang J, Huang Y, Shieh JT, Kwon C, Srivastava D. A genome-wide screen reveals a role for microRNA-1 in modulating cardiac cell polarity. *Dev Cell*. 2011;20:497–510. doi: 10.1016/j.devcel.2011.03.010.

134. Qian L, Liu J, Bodmer R. Slit and Robo control cardiac cell polarity and morphogenesis. *Curr Biol*. 2005;15:2271–2278. doi: 10.1016/j.cub.2005.10.037.

135. Tousi SE, Soltani BM, Sadeghizadeh M, Mowla SJ, Parsi S, Soleimani M. Inhibitory effect of hsa-miR-590-5p on cardiosphere-derived stem cells differentiation through downregulation of TGFB signaling. *J Cell Biochem*. 2015;116:179–191. doi: 10.1002/jcb.24957.

136. Zhao J, Feng Y, Yan H, Chen Y, Wang J, Chua B, Stuart C, Yin D. β-arrestin2/miR-155/GSK3β regulates transition of 5'-azacytizine-induced Sca-1-positive cells to cardiomyocytes. *J Cell Mol Med*. 2014;18:1562–1570. doi: 10.1111/jcmm.12339.

137. Sirish P, López JE, Li N, Wong A, Timofeyev V, Young JN, Majdi M, Li RA, Chen HS, Chiamvimonvat N. MicroRNA profiling predicts a variance in the proliferative potential of cardiac progenitor cells derived from neonatal and adult murine hearts. *J Mol Cell Cardiol*. 2012;52:264–272. doi: 10.1016/j.yjmcc.2011.10.012.

138. Liang D, Zhen L, Yuan T, et al. miR-10a regulates proliferation of human cardiomyocyte progenitor cells by targeting GATA6. *PLoS One*. 2014;9:e103097. doi: 10.1371/journal.pone.0103097.

139. Yang X, Marcucci K, Anguela X, Couto LB. Preclinical evaluation of an anti-HCV miRNA cluster for treatment of HCV infection. *Mol Ther*. 2013;21:588–601. doi: 10.1038/mt.2012.247.

140. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. *Nat Rev Drug Discov*. 2012;11:860–872. doi: 10.1038/nrd3864.

141. Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. *Nat Rev Genet*. 2014;15:445–451. doi: 10.1038/nrg3742.

142. Tilemann L, Ishikawa K, Weber T, Hajjar RJ. Gene therapy for heart failure. *Circ Res*. 2012;110:777–793. doi: 10.1161/CIRCRESAHA.111.252981.

143. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. *Mol Ther*. 2000;1:376–382. doi: 10.1006/mthe.2000.0050.

144. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature*. 2008;456:980–984. doi: 10.1038/nature07511.

145. Hornstein E, Shomron N. Canalization of development by microRNAs. *Nat Genet*. 2006;38(suppl):S20–S24. doi: 10.1038/ng1803.

MicroRNAs and Cardiac Regeneration

Conrad P. Hodgkinson, Martin H. Kang, Sophie Dal-Pra, Maria Mirotsou and Victor J. Dzau

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circres.ahajournals.org/content/116/10/1700